2024
The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation.
Chatenoud L, Herold K, Bach J, Bluestone J. The Teplizumab Saga: The Challenge of Not Getting Lost in Clinical Translation. Cold Spring Harbor Perspectives In Medicine 2024, a041600. PMID: 39284671, DOI: 10.1101/cshperspect.a041600.Peer-Reviewed Original ResearchThe immunology of type 1 diabetes
Herold K, Delong T, Perdigoto A, Biru N, Brusko T, Walker L. The immunology of type 1 diabetes. Nature Reviews Immunology 2024, 24: 435-451. PMID: 38308004, PMCID: PMC7616056, DOI: 10.1038/s41577-023-00985-4.Peer-Reviewed Original ResearchType 1 diabetesT cellsDestruction of pancreatic B-cellsImmune-targeted interventionsTarget T cellsPathogenesis of T1DB-cell massPancreatic B-cellsAutoimmune destructionB cellsGlucose dysregulationImmune mechanismsImmune systemNatural historyDisease pathogenesisT1DRegulatory approvalTreatment of individualsDiscovery of insulinPathogenesisDiseaseSeminal discoveriesImmunotherapy
2023
Checkpoint kinase 2 controls insulin secretion and glucose homeostasis
Chong A, Vandana J, Jeng G, Li G, Meng Z, Duan X, Zhang T, Qiu Y, Duran-Struuck R, Coker K, Wang W, Li Y, Min Z, Zuo X, de Silva N, Chen Z, Naji A, Hao M, Liu C, Chen S. Checkpoint kinase 2 controls insulin secretion and glucose homeostasis. Nature Chemical Biology 2023, 20: 566-576. PMID: 37945898, PMCID: PMC11062908, DOI: 10.1038/s41589-023-01466-4.Peer-Reviewed Original ResearchGlucose-stimulated insulin secretionInsulin secretionHuman β-cellsCynomolgus macaquesΒ-cellsImproved glucose clearanceType 2 diabetic human isletsDiabetic mouse modelDiabetic human isletsHuman β-cell lineDiscovery of insulinT2D conditionsΒ-cell lineGlucose toleranceGlucose clearanceMouse modelGlucose homeostasisMice showHuman isletsSecretionVivo studiesUntargeted metabolic profilingCell linesCheckpoint kinase 2Islets
2022
Pathophysiology and management of hypoglycemia in diabetes
Sanchez‐Rangel E, Deajon‐Jackson J, Hwang JJ. Pathophysiology and management of hypoglycemia in diabetes. Annals Of The New York Academy Of Sciences 2022, 1518: 25-46. PMID: 36202764, DOI: 10.1111/nyas.14904.Peer-Reviewed Original ResearchConceptsType 1 diabetes mellitusCounter-regulatory hormonal responsesMechanism of hypoglycemiaDuration of diabetesManageable chronic diseaseOptimal glycemic controlManagement of hypoglycemiaTreatment of hypoglycemiaNew insulin formulationsDiscovery of insulinGlycemic controlDiabetes mellitusTherapeutic optionsBrain glucoseChronic diseasesNovel therapiesDiabetes managementHypoglycemiaPharmacologic targetHormonal responsesInsulin formulationsDiabetesPatientsCurrent literatureDelivery devices
2000
Diabetic Vascular Disease: Biochemical and Molecular Perspectives
Kamal K, Chang R, Sumpio B. Diabetic Vascular Disease: Biochemical and Molecular Perspectives. 2000, 817-834. DOI: 10.1007/978-1-4612-1190-7_68.Peer-Reviewed Original ResearchDiabetes mellitusChronic complicationsMajor chronic complicationsEnd-organ damageCharacteristic pathological featuresDiscovery of insulinDiabetic patientsDiabetic angiopathyMetabolic abnormalitiesChronic hyperglycemiaPathological featuresVascular diseaseMellitusNatural historyComplicationsDiabetesPatientsAngiopathyMorbidityHyperglycemiaNerveKidneyMortalityAbnormalitiesInsulin
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply